All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Complement Factor H is a Novel Biomarker for Diagnosis and Prognosis of Patients with Liver Cancer

Author(s): C. X. Lv, Qiqi Zhang, Chunyu Li, Y. G. Li, E. T. Li, Z. R. Li and T. C. Wang*
Key Laboratory of Molecular Epigenetics, Institute of Genetics and Cytology, Northeast Normal University, Changchun, Jilin 130024, 1Department of Virology, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences,Changchun, Jilin 130122, 2Department of Academic Affairs, North Sichuan College of Preschool Teacher Education, Guangyuan 628000, Sichuan, 3Department of Agriculture and Animal Husbandry, Fuxin Higher Training College, Fuxin, Liaoning 123000, 4Department of Animal Husbandry, College of Veterinary Medicine, Jilin University, Changchun, Jilin 130000, China

Correspondence Address:
T. C. Wang, Department of Virology, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences,Changchun, Jilin 130122, China, E-mail:

The complement system played critical roles in antimicrobial defense response, immune regulation and immunopathological damage. As an important negative regulator in this system, complement factor H provided selective advantage for tumor cell proliferation to escape immune surveillance, leading to avoid apoptosis. However, the influence of its expression on the pathological process and prognosis of liver cancer were still unclear. In this study, we analyzed the pattern of complement factor H expression in liver cancer in order to clarify its potential application value in the diagnosis and prognosis by bioinformatics analysis of data-set collected from The Cancer Genome Atlas database. By evaluating the clinical diagnostic value of complement factor H, we studied the correlation between complement factor H expression and clinicopathological parameters of liver cancer. Additionally, we found that patients with low complement factor H expression had poor overall survival and relapse-free survival, and confirmed that low complement factor H expression was an independent predictor of poor prognosis through risk regression analysis. Gene-set enrichment analysis identified E2 factor targets, growth 2 phase of mitosis checkpoint, spermatogenesis, mitotic spindle, deoxyribonucleic acid repair and wingless-related integration site/beta-catenin signaling were enriched with low complement factor H expression phenotype. Taking together, these findings suggested that complement factor H may be a useful biomarker for the diagnosis and prognosis of liver cancer.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report